23 C
New York
Sunday, June 14, 2026

Tag: TRI

newssourceFORcompanyinformationcontent1marketreleases

Delivering Wi-Fi 7 Without the Price Tag: EnGenius Announces Affordable ECW520 Access Point

EnGenius ECW520: Bridging Enterprise Wi-Fi 7 Power with SMB Affordability COSTA MESA, Calif., July 16, 2025 /PRNewswire/ -- EnGenius Technologies Inc., a global leader in advanced...

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

Made Scientific and Sentinel BioTherapeutics Announce Strategic Manufacturing Partnership to Advance Ph I/II Allogeneic ePP Encapsulated Cell Therapy Program

PRINCETON, N.J. and HOUSTON, July 15, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Sentinel...

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the...

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...

On Time Trucking Achieves ISO 9001:2015 Certification

New York trucking company completes rigorous assessment and audit of operating processes and procedures, receives certification for quality management systems.Reinforces company's 40 years of...

Jeep® Brand Introduces Two New Special-Edition Wagoneer Models

AUBURN HILLS, Mich., July 11, 2025 /PRNewswire/ --  ...

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase...

ZTE’s “Signal Reach Program” Wins WSIS 2025 Champion Award

GENEVA, July 10, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, stood out from...

Tri Pointe Homes Announces the Grand Opening of Altis at Serenity, Its First 55+ Lifestyle Brand Community on the East Coast in the Research...

With a New Home Gallery now open and sales underway, Altis at Serenity offers 55+ homebuyers a premium lifestyle neighborhood within the 550-acre Serenity planned community near the high-growth town of Fuquay-Varina 
With a New Home Gallery now open and sales underway, Altis at Serenity offers 55+ homebuyers a premium lifestyle neighborhood within the 550-acre Serenity planned community near the high-growth town of Fuquay-Varina

ZTE’s “Signal Reach Program” Wins WSIS 2025 Champion Award

GENEVA, July 10, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, stood out from...

ZTE’s “Signal Reach Program” Wins WSIS 2025 Champion Award

GENEVA, July 10, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, stood out from...

ZTE’s “Signal Reach Program” Wins WSIS 2025 Champion Award

GENEVA, July 10, 2025 /CNW/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, stood out from...

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today...

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers